Literature DB >> 36271076

CRISPR/Cas9-mediated excision of ALS/FTD-causing hexanucleotide repeat expansion in C9ORF72 rescues major disease mechanisms in vivo and in vitro.

Katharina E Meijboom1,2, Abbas Abdallah1, Nicholas P Fordham1, Hiroko Nagase1, Tomás Rodriguez3, Carolyn Kraus3, Tania F Gendron4, Gopinath Krishnan2, Rustam Esanov5, Nadja S Andrade5, Matthew J Rybin5, Melina Ramic5, Zachary D Stephens6, Alireza Edraki3, Meghan T Blackwood1, Aydan Kahriman2, Nils Henninger2, Jean-Pierre A Kocher6, Michael Benatar7, Michael H Brodsky8, Leonard Petrucelli4, Fen-Biao Gao2, Erik J Sontheimer3, Robert H Brown2, Zane Zeier9, Christian Mueller10.   

Abstract

A GGGGCC24+ hexanucleotide repeat expansion (HRE) in the C9ORF72 gene is the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), fatal neurodegenerative diseases with no cure or approved treatments that substantially slow disease progression or extend survival. Mechanistic underpinnings of neuronal death include C9ORF72 haploinsufficiency, sequestration of RNA-binding proteins in the nucleus, and production of dipeptide repeat proteins. Here, we used an adeno-associated viral vector system to deliver CRISPR/Cas9 gene-editing machineries to effectuate the removal of the HRE from the C9ORF72 genomic locus. We demonstrate successful excision of the HRE in primary cortical neurons and brains of three mouse models containing the expansion (500-600 repeats) as well as in patient-derived iPSC motor neurons and brain organoids (450 repeats). This resulted in a reduction of RNA foci, poly-dipeptides and haploinsufficiency, major hallmarks of C9-ALS/FTD, making this a promising therapeutic approach to these diseases.
© 2022. The Author(s).

Entities:  

Year:  2022        PMID: 36271076     DOI: 10.1038/s41467-022-33332-7

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   17.694


  77 in total

1.  Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS.

Authors:  Mariely DeJesus-Hernandez; Ian R Mackenzie; Bradley F Boeve; Adam L Boxer; Matt Baker; Nicola J Rutherford; Alexandra M Nicholson; NiCole A Finch; Heather Flynn; Jennifer Adamson; Naomi Kouri; Aleksandra Wojtas; Pheth Sengdy; Ging-Yuek R Hsiung; Anna Karydas; William W Seeley; Keith A Josephs; Giovanni Coppola; Daniel H Geschwind; Zbigniew K Wszolek; Howard Feldman; David S Knopman; Ronald C Petersen; Bruce L Miller; Dennis W Dickson; Kevin B Boylan; Neill R Graff-Radford; Rosa Rademakers
Journal:  Neuron       Date:  2011-09-21       Impact factor: 17.173

2.  Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons.

Authors:  Yingxiao Shi; Shaoyu Lin; Kim A Staats; Yichen Li; Wen-Hsuan Chang; Shu-Ting Hung; Eric Hendricks; Gabriel R Linares; Yaoming Wang; Esther Y Son; Xinmei Wen; Kassandra Kisler; Brent Wilkinson; Louise Menendez; Tohru Sugawara; Phillip Woolwine; Mickey Huang; Michael J Cowan; Brandon Ge; Nicole Koutsodendris; Kaitlin P Sandor; Jacob Komberg; Vamshidhar R Vangoor; Ketharini Senthilkumar; Valerie Hennes; Carina Seah; Amy R Nelson; Tze-Yuan Cheng; Shih-Jong J Lee; Paul R August; Jason A Chen; Nicholas Wisniewski; Victor Hanson-Smith; T Grant Belgard; Alice Zhang; Marcelo Coba; Chris Grunseich; Michael E Ward; Leonard H van den Berg; R Jeroen Pasterkamp; Davide Trotti; Berislav V Zlokovic; Justin K Ichida
Journal:  Nat Med       Date:  2018-02-05       Impact factor: 53.440

Review 3.  Relationship between C9orf72 repeat size and clinical phenotype.

Authors:  Sara Van Mossevelde; Julie van der Zee; Marc Cruts; Christine Van Broeckhoven
Journal:  Curr Opin Genet Dev       Date:  2017-03-17       Impact factor: 5.578

4.  Frontotemporal dementia associated with the C9ORF72 mutation: a unique clinical profile.

Authors:  Emma Devenney; Michael Hornberger; Muireann Irish; Eneida Mioshi; James Burrell; Rachel Tan; Matthew C Kiernan; John R Hodges
Journal:  JAMA Neurol       Date:  2014-03       Impact factor: 18.302

5.  RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention.

Authors:  Christopher J Donnelly; Ping-Wu Zhang; Jacqueline T Pham; Aaron R Haeusler; Aaron R Heusler; Nipun A Mistry; Svetlana Vidensky; Elizabeth L Daley; Erin M Poth; Benjamin Hoover; Daniel M Fines; Nicholas Maragakis; Pentti J Tienari; Leonard Petrucelli; Bryan J Traynor; Jiou Wang; Frank Rigo; C Frank Bennett; Seth Blackshaw; Rita Sattler; Jeffrey D Rothstein
Journal:  Neuron       Date:  2013-10-16       Impact factor: 17.173

6.  A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD.

Authors:  Alan E Renton; Elisa Majounie; Adrian Waite; Javier Simón-Sánchez; Sara Rollinson; J Raphael Gibbs; Jennifer C Schymick; Hannu Laaksovirta; John C van Swieten; Liisa Myllykangas; Hannu Kalimo; Anders Paetau; Yevgeniya Abramzon; Anne M Remes; Alice Kaganovich; Sonja W Scholz; Jamie Duckworth; Jinhui Ding; Daniel W Harmer; Dena G Hernandez; Janel O Johnson; Kin Mok; Mina Ryten; Danyah Trabzuni; Rita J Guerreiro; Richard W Orrell; James Neal; Alex Murray; Justin Pearson; Iris E Jansen; David Sondervan; Harro Seelaar; Derek Blake; Kate Young; Nicola Halliwell; Janis Bennion Callister; Greg Toulson; Anna Richardson; Alex Gerhard; Julie Snowden; David Mann; David Neary; Michael A Nalls; Terhi Peuralinna; Lilja Jansson; Veli-Matti Isoviita; Anna-Lotta Kaivorinne; Maarit Hölttä-Vuori; Elina Ikonen; Raimo Sulkava; Michael Benatar; Joanne Wuu; Adriano Chiò; Gabriella Restagno; Giuseppe Borghero; Mario Sabatelli; David Heckerman; Ekaterina Rogaeva; Lorne Zinman; Jeffrey D Rothstein; Michael Sendtner; Carsten Drepper; Evan E Eichler; Can Alkan; Ziedulla Abdullaev; Svetlana D Pack; Amalia Dutra; Evgenia Pak; John Hardy; Andrew Singleton; Nigel M Williams; Peter Heutink; Stuart Pickering-Brown; Huw R Morris; Pentti J Tienari; Bryan J Traynor
Journal:  Neuron       Date:  2011-09-21       Impact factor: 17.173

7.  Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study.

Authors:  Elisa Majounie; Alan E Renton; Kin Mok; Elise G P Dopper; Adrian Waite; Sara Rollinson; Adriano Chiò; Gabriella Restagno; Nayia Nicolaou; Javier Simon-Sanchez; John C van Swieten; Yevgeniya Abramzon; Janel O Johnson; Michael Sendtner; Roger Pamphlett; Richard W Orrell; Simon Mead; Katie C Sidle; Henry Houlden; Jonathan D Rohrer; Karen E Morrison; Hardev Pall; Kevin Talbot; Olaf Ansorge; Dena G Hernandez; Sampath Arepalli; Mario Sabatelli; Gabriele Mora; Massimo Corbo; Fabio Giannini; Andrea Calvo; Elisabet Englund; Giuseppe Borghero; Gian Luca Floris; Anne M Remes; Hannu Laaksovirta; Leo McCluskey; John Q Trojanowski; Vivianna M Van Deerlin; Gerard D Schellenberg; Michael A Nalls; Vivian E Drory; Chin-Song Lu; Tu-Hsueh Yeh; Hiroyuki Ishiura; Yuji Takahashi; Shoji Tsuji; Isabelle Le Ber; Alexis Brice; Carsten Drepper; Nigel Williams; Janine Kirby; Pamela Shaw; John Hardy; Pentti J Tienari; Peter Heutink; Huw R Morris; Stuart Pickering-Brown; Bryan J Traynor
Journal:  Lancet Neurol       Date:  2012-03-09       Impact factor: 44.182

8.  C9orf72 intermediate expansions of 24-30 repeats are associated with ALS.

Authors:  Alfredo Iacoangeli; Ahmad Al Khleifat; Ashley R Jones; William Sproviero; Aleksey Shatunov; Sarah Opie-Martin; Karen E Morrison; Pamela J Shaw; Christopher E Shaw; Isabella Fogh; Richard J Dobson; Stephen J Newhouse; Ammar Al-Chalabi
Journal:  Acta Neuropathol Commun       Date:  2019-07-17       Impact factor: 7.801

Review 9.  Amyotrophic lateral sclerosis.

Authors:  Lokesh C Wijesekera; P Nigel Leigh
Journal:  Orphanet J Rare Dis       Date:  2009-02-03       Impact factor: 4.123

10.  Reduced C9ORF72 function exacerbates gain of toxicity from ALS/FTD-causing repeat expansion in C9orf72.

Authors:  Qiang Zhu; Jie Jiang; Tania F Gendron; Melissa McAlonis-Downes; Lulin Jiang; Amy Taylor; Sandra Diaz Garcia; Somasish Ghosh Dastidar; Maria J Rodriguez; Patrick King; Yongjie Zhang; Albert R La Spada; Huaxi Xu; Leonard Petrucelli; John Ravits; Sandrine Da Cruz; Clotilde Lagier-Tourenne; Don W Cleveland
Journal:  Nat Neurosci       Date:  2020-04-13       Impact factor: 24.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.